Michal Bar-Natan, M.D.

Michal Bar-Natan, M.D.

520 East 70th Street Starr Pavilion, 3rd Floor , New York, 10021 (646) 962-2700 Website

Opening hours ( 4 Nov - 10 Nov)

  • This week| Next week

  • Monday

    closed
  • Tuesday

    closed
  • Wednesday

    closed
  • Thursday

    closed
  • Friday

    closed
  • Saturday

    closed
  • Sunday

    closed

Late night shopping

Late night shopping unknown

Late night shopping

Sunday shopping unknown


Company description

Michal Bar-Natan, MD, is Interim Assistant Professor of Medicine and a member of the Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital in New York City. Dr. Bar-Natan graduated cum laude from the Sackler School of Medicine. She completed her Internal Medicine Residency at Sheba Medical Center and her Fellowship in Hematology and Medical Oncology at NYU Langone Health. In addition to her clinical fellowship training, Dr. Bar-Natan completed a research fellowship at Dana Farber Cancer Institute and Brigham and Women’s Hospital (Harvard Medical School) with a focus on the role that signal transducer and activator of transcription (STAT) proteins play in the development and treatment of myeloproliferative neoplasms (MPNs) and leukemias.Prior to this position Dr. Bar-Natan served as Associate Professor of Medicine at the Icahn School of Medicine at Mt. Sinai, an Attending Physician with the Center of Excellence for Blood Cancers and Myeloid Disorders, and as the leader of the Acute Lymphoblastic Leukemia program at the Mt. Sinai Tisch Cancer Institute. Dr. Bar-Natan’s focus is on translational research in malignant hematology, particularly myeloid malignancies and acute lymphoblastic leukemia, and the development of investigator-initiated clinical trials for patients with these conditions. She leads early phase clinical trials implementing new therapeutic approaches, such as immunotherapies and combination therapies, and serves as the PI and co-investigator on many clinical trials for acute leukemias and myeloproliferative neoplasms.